lymphoma

[Critical Reviews in Oncology Hematology] Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.

[Endocrine Journal] Investigators retrospectively analyzed 26 patients with primary thyroid lymphomas and 16 patients with benign lymphoproliferative lesions.

[Blood Advances] Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.

[Blood Advances] 43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.

[Leukemia & Lymphoma] Investigators retrospectively analyzed 55 patients who underwent allogeneic stem cell transplantation for mantle cell lymphoma relapsed or refractory after rituximab and high-dose cytarabine within the MANTLE-FIRST project.

[Sutro Biopharma, Inc.] Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.